Gensight Biologics SA (SIGHT)

Paris
2.24
0.00(0.00%)
  • Volume:
    41,006
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2.20 - 2.29
  • Type:Equity
  • Market:France
  • ISIN:FR0013183985

SIGHT Overview

Prev. Close
2.24
Day's Range
2.2-2.29
Revenue
5.98M
Open
2.24
52 wk Range
1.8-8.69
EPS
-0.63
Volume
41,006
Market Cap
103.57M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
212,533
P/E Ratio
-
Beta
1.74
1-Year Change
-70.23%
Shares Outstanding
46,237,798
Next Earnings Date
Jul 28, 2022
What is your sentiment on Gensight Biologics?
or
Market is currently closed. Voting is open during market hours.

Gensight Biologics SA Company Profile

Gensight Biologics SA Company Profile

Employees
33
Market
France

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralNeutralStrong SellStrong Sell
Technical IndicatorsSellStrong BuyBuyStrong SellStrong Sell
SummaryNeutralBuyNeutralStrong SellStrong Sell
  • management keeps diluting for nothing - they could have waited for the REFLECT study and raise at a higher price. Or they are not confident in the upcoming results.
    0
    • undervalued, a lot of potential with Lumevocq and GS030!
      0
      • yeah check my comments i was pounding the table from last year.
        0
    • undervalued. Today announced sustained efficacy.
      0
      • I didn't suspect this being strong lately
        0
        • It is strongly growing till sept with end of phase 3 and positive results expected
          0